Neuropathology of Aging and Alzheimer’s Disease takes a foundational approach to the topic by offering basic scientific information and the latest advancements in the field. The focus of this reference is on neuropathology and recent advances in tissue characterization in aging, and in Alzheimer’s Disease. Neuropathology has direct relevance to therapeutic constructs and allows for an in-depth understanding of disease pathogenesis. It is a synthesis of the salient issues with respect to pathology, pathogenesis, diagnosis, disease, normal aging, biomarker relevance, and prospects for therapeutic intervention.
Les mer
Part I: Alzheimer and his contemporaries 1. Alzheimer’s disease: a fortuitous beginning 2. Alzheimer’s first case 3. Alzheimer’s second case and the naming of Alzheimer’s disease 4. Some early observations of Alzheimer’s contemporaries 5. Early studies on senile dementia and aging 6. The human element References 000 Part II: The dark ages 7. The 1920s and 1930s 8. The 1940s to the 1960s Part III: Beyond plaques and tangles: lewy bodies, vascular disease, and the rise of the acronyms 9. Lewy bodies 10. The role of vascular disease in Alzheimer’s disease neuropathology Atherosclerosis 11. The rise of the acronym References 12. Aging-related neuronal tau 13. Aging and disease-related astrocytic tau 14. TDP-43 in aging and Alzheimer’s disease 15. Argyrophilic grain disease Part IV: Alzheimer’s disease, dementia pugilistica, and the influence of neuropathology 16. Introduction to the traumatic brain injury--neurodegenerative disease dichotomy 17. Punch drunk syndrome: the first 30 years 18. Clinicopathological analysis from the 1950s and 1960s 19. 1970 to 2000: transitioning to an immunohistochemistry--only diagnosis 20. The modern chronic traumatic encephalopathy era 21. Postmortem of punch drunk boxers and chronic traumatic encephalopathy Part V: Familial alzheimer’s disease, down syndrome, and the amyloid cascade hypothesis 22. Familial Alzheimer’s disease and Down syndrome 23. The amyloid cascade hypothesis Part VI: Practical considerations in the diagnosis of alzheimer’s disease and aging 24. Application of consensus criteria 25. The diagnostic process
Les mer
A complete resource on the pathology, pathogenesis, and pathophysiology of Alzheimer's Disease, providing clinical aspects for a better understanding of the disease
Detailed discussion and analysis of early Alzheimer’s disease investigators and their findings Detailed discussion and analysis of the often-overlooked literature from the 1920’s to the 1960’s Detailed discussion and analysis of aging-related phenomena currently under study Detailed discussion and analysis of punch-drunk syndrome and the transition to modern understanding of chronic traumatic encephalopathy Detailed discussion and analysis of the pathology of autosomal dominant Alzheimer’s disease and Alzheimer’s disease associated with Down syndrome Practical issues with diagnosing and reporting Alzheimer’s disease and aging-related changes
Les mer

Produktdetaljer

ISBN
9780323996518
Publisert
2025-05-21
Utgiver
Elsevier - Health Sciences Division; Elsevier - Health Sciences Division
Vekt
450 gr
Høyde
235 mm
Bredde
191 mm
Aldersnivå
P, UP, 06, 05
Språk
Product language
Engelsk
Format
Product format
Heftet
Antall sider
350

Om bidragsyterne

Dr. Rudy Castellani is a professor in the Division of Neuropathology at the Northwestern University Feinberg School of Medicine, the Program Director for the Neuropathology Fellowship Training Program, and the Neuropathology Core Director for the Northwestern University Alzheimer’s Disease Research Center at the Mesulam Center for Cognitive Neurology. He is the recipient of the 2010 Alzheimer medal from the Journal of Alzheimer’s disease. He was formerly professor and vice chair of research, at West Virginia University and the Rockefeller Neuroscience institute, and a former tenured professor and director of neuropathology at University of Maryland, Baltimore. Dr. Castellani has authored or co-authored over 330 research articles, reviews, and chapters, with a focus on neurodegenerative diseases and neurotrauma, and has been quoted in the New York Times on issues related to Alzheimer’s disease treatment.